QM · rank #10 · 2026-09-07
CDNA
NASDAQ · $2.63B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +290.06% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +29.5% |
| Profit margin Net profit margin, trailing 12 months. | +24.2% |
| Market cap (USD) Size filter: > $500M required. | $2.63B |
| Anchor (recent) Close on 2026-08-07 | $46.69 |
| Anchor (far) Close on 2025-08-08 | $11.97 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
CareDx is a precision medicine diagnostics company focused on solid organ transplant, specialty oncology, and cell therapy, generating revenue primarily through high-margin testing services augmented by AI-driven analytics.
Rationale
The momentum_12_1 of 2.91 and ROE of 29% with a 24% profit margin reflect a genuine inflection in operating quality — 52% revenue growth, 74% non-GAAP gross margins, and a debt-free balance sheet with $374M cash confirm the quant signals are grounded in fundamental improvement, not noise.
Material risks
- 1Medicare LCD reimbursement risk is already embedded in guidance, meaning any adverse coverage expansion or CMS policy shift beyond the current six-month estimate could directly impair the testing services revenue line that drives 76% of Q2 revenue.
- 2The simultaneous integration of NavDx oncology and the VANTx AI platform post-divestiture concentrates execution risk at exactly the moment the company is pivoting its growth narrative away from its legacy lab products anchor.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.